Previous Article | Next Article ![]()
Antimicrobial Agents and Chemotherapy, July 2007, p. 2594-2596, Vol. 51, No. 7
0066-4804/07/$08.00+0 doi:10.1128/AAC.00580-06
Copyright © 2007, American Society for Microbiology. All Rights Reserved.

,
Andrea Giacometti,2,
Oscar Cirioni,2
Roberto Ghiselli,3
Fiorenza Orlando,4
Vittorio Saba,3
Giorgio Scalise,2
Milica Sevo,5
Marina Tuzova,7
Robin Patel,1,6 and
Naomi Balaban5*
Division of Infectious Diseases, Mayo Clinic College of Medicine, Rochester, Minnesota,1 Institute of Infectious Diseases and Public Health, Università Politecnica delle Marche, Ancona, Italy,2 Department of General Surgery, I.N.R.C.A. I.R.R.C.S., Università Politecnica delle Marche, Ancona, Italy,3 Experimental Animal Models for Aging Units, Research Department, I.N.R.C.A. I.R.R.C.S., Ancona, Italy,4 Tufts University, Veterinary School, North Grafton, Massachusetts,5 Division of Clinical Microbiology, Mayo Clinic College of Medicine, Rochester, Minnesota,6 Boston University, Boston, Massachusetts7
Received 11 May 2006/ Returned for modification 31 August 2006/ Accepted 10 November 2006
Staphylococci, common orthopedic pathogens, form antibiotic-resistant biofilms. Polymethylmethacrylate (PMMA) beads loaded with the quorum-sensing inhibitor RNAIII-inhibiting peptide (RIP) were implanted in rats and shown to prevent methicillin-resistant Staphylococcus aureus infection. RIP release was bimodal, typical of previously-tested antibiotics. These results suggest that RIP-PMMA warrants further evaluation for management of orthopedic infections caused by staphylococci.
Published ahead of print on 20 November 2006.
Both authors contributed equally.
Present address: Department of Clinical Microbiology, Hospital Gregorio Marañon, Madrid, Spain.
This article has been cited by other articles:
Copyright © 2009 by the American Society for Microbiology. For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»